Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Avutometinib and defactinib |
| Trade Name | Avmapki Fakzynja Co-pack |
| Synonyms | |
| Drug Descriptions |
Avmapki Fakzynja Co-pack (avutometinib and defactinib) is a combination drug that consists of the RAF/MEK inhibitor Avutometinib and the FAK inhibitor Defactinib, which may synergistically inhibit tumor growth (PMID: 39240189). Avmapki Fakzynja Co-pack (avutometinib and defactinib) is FDA-approved for use in patients with KRAS-mutant recurrent low-grade serous ovarian cancer (FDA.gov). |
| DrugClasses | FAK inhibitor 16 MEK inhibitor (Pan) 27 MEK1 Inhibitor 27 MEK2 Inhibitor 25 RAF Inhibitor (Pan) 29 |
| CAS Registry Number | |
| NCIT ID |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avutometinib and defactinib | Avutometinib and defactinib | 0 | 0 |